AptuCure Bio
Personalized Therapeutics
Company Overview
Snapshot
Founded in January 2015 by Ofer Nussbaum, Ph.D. and Boaz Musafia, AptuCure Bio operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing innovative therapeutic solutions.
Business overview
AptuCure Bio is a Health Tech & Life Sciences company specializing in the development of personalized therapeutics. The company's core technology revolves around AptuBodies, which are unique synthetic aptamer-based nanoparticles designed to mimic antibody activity. These AptuBodies can be directed against virtually any target, binding non-covalently to the Fab fragment of circulating IgG antibodies to create a new antigen binding domain. This mechanism allows the AptuBody/IgG complex to mimic therapeutic antibodies, promoting the activation of the natural immune system to target and eliminate cells in conditions such as cancer, infectious diseases, and autoimmune disorders. AptuCure Bio operates within the Pharmaceuticals sector, serving the Drugs Discovery & Development market.
Company Intelligence Q&A
- What is AptuCure Bio's primary focus?
- AptuCure Bio is focused on developing personalized therapeutics, specifically AptuBodies, which are synthetic aptamer-based nanoparticles designed to mimic antibody activity for targeted treatment of various diseases.
- When was AptuCure Bio founded?
- AptuCure Bio was founded in January 2015.
- Who are the founders of AptuCure Bio?
- AptuCure Bio was founded by Ofer Nussbaum, Ph.D. and Boaz Musafia.
- What is the core technology behind AptuCure Bio's therapeutics?
- The core technology involves AptuBodies, which are unique synthetic aptamer-based nanoparticles that bind to circulating IgG antibodies, directing them to specific cell surface markers and activating the natural immune system to target cells.
- What types of diseases are AptuCure Bio's AptuBodies designed to treat?
- AptuCure Bio's AptuBodies are designed for the treatment of cancer, infectious diseases, and autoimmune diseases by promoting a complement-mediated immune response.